alpha-Interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia

被引:30
作者
Giardini, C
Galimberti, M
Lucarelli, G
Polchi, P
Angelucci, E
Baronciani, D
Erer, B
Gaziev, D
Piga, A
DiGregorio, F
Romeo, MA
Mangiagli, A
Petrelli, E
Muretto, P
机构
[1] AZIENDA OSPED PESARO,CTR TRAPIANTO MIDOLLO OSSEO MURAGLIA,I-61100 PESARO,ITALY
[2] UNIV TURIN,IST CLIN PEDIAT,CTR MICROCITEMIE,TURIN,ITALY
[3] UNIV CATANIA,DIV PEDIAT,CATANIA,ITALY
[4] OSPED UMBERTO 1,DIV PEDIAT,SIRACUSA,ITALY
[5] AZIENDA OSPED PESARO,DIV MALATTIE INFETTIVE,I-61100 PESARO,ITALY
[6] AZIENDA OSPED PESARO,SERV ANAT PATOL,I-61100 PESARO,ITALY
关键词
interferon; HCV; thalassemia; BMT;
D O I
10.1038/sj.bmt.1700968
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
No experience has been reported to date in treating chronic hepatitis C virus (HCV) infection with interferon (IFN) therapy after BMT, mainly due to concerns related to the impact of an immunomodulatory drug in patients who are immunologic and haematologic chimeras, However, chronic inflammatory activity related to HCV infection results in a chronic fibrogenous mechanism potentially leading to liver cirrhosis and hepatocellular carcinoma. Moreover, patients transplanted for P-thalassemia could be at greater risk because of concomitant iron overload and pre-existing fibrous liver damage, Eleven patients with serological, biochemical, histological and molecular biological evidence of HCV infection were included in the study and treated for 6-12 months with recombinant IFN 24-65 months following BMT, The serum alanine aminotransferase (ALT) was persistently elevated (range 85-1242 U/l; mean 416) for at least 1 year prior to IFN treatment, Ten patients completed the protocol; five were considered as responders to treatment, In these five patients the liver histology showed an overall reduction of inflammation and necrosis: histological inflammatory activity improved from chronic active hepatitis (CAH) to chronic persistent hepatitis (three patients) or minimal residual inflammatory activity (two patients), The Knodell total activity score varied from 5.4 (range 3-9) to 1.4 (range 1-2; P = 0.05), All responding patients revealed negativization of serum HCV-RNA, that has been persistent in four (follow-up 1-3 years), ALT level fell to 15-80 U/l (mean 52; P = 0.0027), No major complications occurred during the therapy and no influence on marrow engraftment parameters were noted. We conclude that IFN therapy does not adversely interfere with engraftment and that it is a feasible therapy for treatment of chronic hepatitis C virus after BMT.
引用
收藏
页码:767 / 772
页数:6
相关论文
共 33 条
  • [1] Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation
    Angelucci, E
    Muretto, P
    Lucarelli, G
    Ripalti, M
    Baronciani, D
    Erer, B
    Galimberti, M
    Giardini, C
    Gaziev, D
    Polchi, P
    Rovelli, A
    Monguzzi, W
    Masera, G
    Piga, A
    Garofalo, F
    Gabutti, V
    DiGregorio, F
    Romeo, MA
    Cammella, A
    Russo, G
    Gallisai, D
    Burrai, C
    Costi, C
    Marinaro, AM
    Erbeia, M
    Mazzani, D
    Nobili, B
    Perrotta, S
    Ferrara
    Cutillo, S
    Mulas, G
    Careddu, F
    Mancini, E
    Argiolu, F
    Addari, C
    Ruggiero, L
    DeNunzio, A
    Terzoli, S
    DAscola, G
    Bruciatelli, M
    Satta, AM
    BorgnaPignatti, C
    Marradi, P
    Puggioni, G
    Murgia, T
    Porta, E
    Poggi, V
    PintaBoccalatte, MF
    Polizzi, B
    Maroni, P
    [J]. BLOOD, 1997, 90 (03) : 994 - 998
  • [2] ARCESE W, 1990, BONE MARROW TRANSPL, V5, P309
  • [3] BARTON AL, 1995, AM J CLIN PATHOL, V103, P419
  • [4] CHRONIC HEPATITIS-C AFTER RENAL-TRANSPLANTATION - TREATMENT WITH ALPHA-INTERFERON
    CHAN, TM
    LOK, ASF
    CHENG, IKP
    NG, IOL
    [J]. TRANSPLANTATION, 1993, 56 (05) : 1095 - 1098
  • [5] EFFECT OF IRON OVERLOAD ON THE RESPONSE TO RECOMBINANT INTERFERON-ALFA TREATMENT IN TRANSFUSION-DEPENDENT PATIENTS WITH THALASSEMIA MAJOR AND CHRONIC HEPATITIS-C
    CLEMENTE, MG
    CONGIA, M
    LAI, ME
    LILLIU, F
    LAMPIS, R
    FRAU, F
    FRAU, MR
    FAA, G
    DIANA, G
    DESSI, C
    MELIS, A
    MAZZOLENI, AP
    CORNACCHIA, G
    CAO, A
    DEVIRGILIIS, S
    [J]. JOURNAL OF PEDIATRICS, 1994, 125 (01) : 123 - 128
  • [6] TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL
    DAVIS, GL
    BALART, LA
    SCHIFF, ER
    LINDSAY, K
    BODENHEIMER, HC
    PERRILLO, RP
    CAREY, W
    JACOBSON, IM
    PAYNE, J
    DIENSTAG, JL
    VANTHIEL, DH
    TAMBURRO, C
    LEFKOWITCH, J
    ALBRECHT, J
    MESCHIEVITZ, C
    ORTEGO, TJ
    GIBAS, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1501 - 1506
  • [7] DESOUZA MHO, 1992, BONE MARROW TRANSPL, V9, P495
  • [8] RECOMBINANT INTERFERON-ALFA THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    DIBISCEGLIE, AM
    MARTIN, P
    KASSIANIDES, C
    LISKERMELMAN, M
    MURRAY, L
    WAGGONER, J
    GOODMAN, Z
    BANKS, SM
    HOOFNAGLE, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) : 1506 - 1510
  • [9] DIMARCO V, 1992, HAEMATOLOGICA, V77, P502
  • [10] ALPHA INTERFERON IN THE TREATMENT OF CHRONIC HEPATITIS-C INFECTION IN THALASSEMIA MAJOR
    DONOHUE, SM
    WONKE, B
    HOFFBRAND, AV
    REITTIE, J
    GANESHAGURU, K
    SCHEUER, PJ
    BROWN, D
    DUSHEIKO, G
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1993, 83 (03) : 491 - 497